SEC Form 4 · accession 0001203311-16-000185
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Darren S Cline
Officer — EVP, Commercial
Period of report
Dec 16, 2016
Accepted (ET)
Dec 20, 2016 · 7:48 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 16, 2016 | M | 3,100 | $16.41 | A | 61,604 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Incentive Stock Option (right to buy)F2 | $16.41 | Dec 16, 2016 | M | 3,100 | D | — | Oct 29, 2020 | Common Stock | 3,100 | 5,024 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2Shares vested at a rate of 25% on 10/29/11 and monthly thereafter until all the shares were fully vested on 10/29/14.